Insights

Innovative Technology Collaboration Daiichi Sankyo France recently partnered with Depixus to leverage MAGNA(TM) technology for RNA-targeted drug discovery, indicating a strategic focus on cutting-edge research tools that could lead to new therapeutic opportunities and potential sales avenues.

Therapeutic Portfolio Focus The company specializes in treatments for major health conditions such as cancer, cardiovascular diseases, and inflammatory disorders, suggesting opportunities to provide complementary healthcare solutions, support services, or advanced formulations targeting these high-demand areas.

Growing Market Presence As part of the global Japanese pharmaceutical group, Daiichi Sankyo France benefits from the international brand strength and expanding footprint, making it an attractive partner for collaborations in research, clinical trials, and supply chain network expansion.

Technological Infrastructure With a modern tech stack that includes TYPO3, OneTrust, and secure server configurations, the company values digital security and efficient online presence, providing opportunities for collaborative digital solutions or cybersecurity services.

Financial and Market Potential With revenues estimated between 10 and 25 million dollars and a dedicated team of up to 200 employees, there is scope to approach for mid-sized enterprise solutions, partnership opportunities, and strategic sales tailored to growing pharmaceutical organizations.

Similar companies to Daiichi Sankyo France

Daiichi Sankyo France Tech Stack

Daiichi Sankyo France uses 8 technology products and services including TYPO3, OneTrust, Apple iCloud Mail, and more. Explore Daiichi Sankyo France's tech stack below.

TYPO3
Content Management System
OneTrust
Cookie Compliance
Apple iCloud Mail
Email
PHP
Programming Languages
HSTS
Security
X-XSS-Protection
Security
Apache
Web Servers
Apache HTTP Server
Web Servers

Media & News

Depixus partners with Daiichi Sankyo.
PARIS, France - Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA(TM) technology to accelerate the Japanese healthcare leader's RNA-targeted drug discovery program.
Dec 12, 2023 | depixus.com

Daiichi Sankyo France's Email Address Formats

Daiichi Sankyo France uses at least 2 format(s):

Daiichi Sankyo France Email Formats	Example	Percentage
FLast@dsi.com	JDoe@dsi.com	89%
LFirst@dsi.com	DJohn@dsi.com	7%
FiLast@dsi.com	JoDoe@dsi.com	1%
First.Last@dsi.com	John.Doe@dsi.com	1%
FL@dsi.com	JD@dsi.com	1%
FirLast@dsi.com	JohDoe@dsi.com	1%
First.Last@daiichi-sankyo.fr	John.Doe@daiichi-sankyo.fr	83%
Last.First@daiichi-sankyo.fr	Doe.John@daiichi-sankyo.fr	17%

Frequently Asked Questions

Where is Daiichi Sankyo France's headquarters located?

Daiichi Sankyo France's main headquarters is located at 8-10 Rue Henri Sainte-claire Deville Rueil-malmaison, Île-de-france 92500 France. The company has employees across 4 continents, including EuropeNorth AmericaAsia.

What is Daiichi Sankyo France's official website and social media links?

Daiichi Sankyo France's official website is daiichi-sankyo.fr and has social profiles on LinkedIn.

What is Daiichi Sankyo France's NAICS code?

Daiichi Sankyo France's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Daiichi Sankyo France have currently?

As of February 2026, Daiichi Sankyo France has approximately 179 employees across 4 continents, including EuropeNorth AmericaAsia. Key team members include Head Of Msl: F. D.Head Of Msls Lung & Gastric Cancers: G. L. G.Head Of Regulatory Affairs & Quality Assurance: A. C.. Explore Daiichi Sankyo France's employee directory with LeadIQ.

What industry does Daiichi Sankyo France belong to?

Daiichi Sankyo France operates in the Pharmaceutical Manufacturing industry.

What technology does Daiichi Sankyo France use?

Daiichi Sankyo France's tech stack includes TYPO3OneTrustApple iCloud MailPHPHSTSX-XSS-ProtectionApacheApache HTTP Server.

What is Daiichi Sankyo France's email format?

Daiichi Sankyo France's email format typically follows the pattern of FLast@dsi.com. Find more Daiichi Sankyo France email formats with LeadIQ.

When was Daiichi Sankyo France founded?

Daiichi Sankyo France was founded in 2002.

Daiichi Sankyo France

Q: How many employees does Daiichi Sankyo France have currently?

Daiichi Sankyo France has approximately 179 employees.

Q: What technology does Daiichi Sankyo France use?

Daiichi Sankyo France's tech stack includes Apache, Google Tag Manager, jsDelivr, DocuSign, Google Analytics.

Pharmaceutical ManufacturingÎle-de-france, France51-200 Employees

Daiichi Sankyo est un groupe pharmaceutique mondial japonais, basé à Tokyo (Japon) et présent dans plus de cinquante pays.

Né de la fusion en 2005 des laboratoires Daiichi et Sankyo, nous figurons aujourd’hui parmi les 25 laboratoires pharmaceutiques les plus importants au monde et comptons plus de 16 000 salariés dans plus de 20 pays dans le monde. 

Daiichi Sankyo commercialise de nombreux traitements destinés à lutter contre des pathologies importantes : hypertension, dyslipidémie, diabète, syndrome coronaire aigu, maladie thromboembolique veineuse, cancer du sein, mélanome métastasique, maladies inflammatoires, douleur.

Daiichi Sankyo France est une filiale de Daiichi Sankyo Europe GmbH dont le siège est situé à Munich.

Company Overview

Headquarters: 8-10 Rue Henri Sainte-claire Deville Rueil-malmaison, Île-de-france 92500 France
Website: daiichi-sankyo.fr
NAICS Code: 3254 - Pharmaceutical and Medicine Manufacturing
Founded: 2002
Employees: 51-200